Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Payables: 2023-2025

Historic Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $17.9 million.

  • Monte Rosa Therapeutics' Payables rose 18.56% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.7 million, marking a year-over-year increase of 25.52%. This contributed to the annual value of $18.8 million for FY2024, which is 28.66% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Payables of $17.9 million as of Q3 2025, which was up 30.04% from $13.8 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Payables high stood at $18.8 million for Q4 2024, and its period low was $10.2 million during Q1 2023.
  • Moreover, its 3-year median value for Payables was $14.2 million (2023), whereas its average is $14.1 million.
  • Data for Monte Rosa Therapeutics' Payables shows a peak YoY skyrocketed of 52.03% (in 2025) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Payables (Quarterly) stood at $14.6 million in 2023, then climbed by 28.66% to $18.8 million in 2024, then increased by 18.56% to $17.9 million in 2025.
  • Its Payables was $17.9 million in Q3 2025, compared to $13.8 million in Q2 2025 and $16.3 million in Q1 2025.